BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+(TM) in Breast and Prostate Cancer Models

Executive Summary

• BriaCell will present pre‑clinical evidence of strong immune engagement and anti‑cancer activity for its next‑generation Bria‑OTS+ platform at the SITC 40th Anniversary Annual Meeting on November 7, 2025.
• Lead candidates Bria‑BRES+ (breast cancer) and Bria‑PROS+ (prostate cancer) have completed GMP manufacturing and are slated for Phase 1/2a clinical trials, with Bria‑PROS+ supported by a $2 M NCI SBIR award.
• The poster will detail extensive immune activation and cytotoxicity data, underscoring the platform’s potential to overcome immune resistance in cancer therapy.

Key Details

• Presentation Information – Title: “Redefining Cancer Vaccines: Bria‑OTS+ Integrates Trained Innate Immunity and Adaptive Memory to Overcome Immune Resistance”; Abstract No. 353; Poster displayed Friday, Nov 7, 2025, 12:15–1:45 PM & 5:35–7 PM ET at Prince George ABC Exhibit Hall, National Harbor, MD.
• Platform Overview – Bria‑OTS+ is an enhanced off‑the‑shelf immunotherapy platform expressing multiple immune‑activating cytokines and co‑stimulatory molecules to boost both innate and adaptive anti‑tumor responses.
• Lead Candidates –
• Bria‑BRES+ (breast cancer) – GMP‑manufactured, pending Phase 1/2a evaluation.
• Bria‑PROS+ (prostate cancer) – GMP‑manufactured; Phase 1/2a trial to be funded in part by a $2 M NCI Small Business Innovative Research award announced Aug 25, 2025.
• Funding Support – $2 M NCI SBIR award earmarked for manufacturing scale‑up and planned clinical evaluation of Bria‑PROS+.
• Data Highlights (to be presented) – Pre‑clinical models demonstrate robust immune system activation, high cytotoxicity against cancer cells, and selective sparing of normal tissue. Specific quantitative results were not disclosed in the release but will be detailed on the poster.
• Poster Access – A digital copy of the poster will be posted at https://briacell.com/scientific‑publications/.

Notable Quotes

• “We are very excited with this opportunity to showcase the activity of our novel Bria‑OTS+ platform which is designed to reinvigorate the body’s immune system to powerfully and selectively attack cancer cells while sparing normal tissues,” – Miguel A. Lopez‑Lago, PhD, Chief Scientific Officer.
• “We look forward to evaluating these encouraging results in upcoming clinical studies of Bria‑BRES+ for breast cancer and Bria‑PROS+ for prostate cancer, as we strive to bring new hope to patients with unmet medical needs,” – Dr. William V. Williams, President & CEO.